Novavax COVID-19 vaccine shows almost 90% efficacy in Phase III trial
January 29, 2021Medical Communications COVID-19, Novavax
Novavax has announced that its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated an efficacy of 89.3% in its UK Phase III trial. …
Toxys and Leiden University to commercialise and develop animal-free toxicity testing platform
January 29, 2021Medical Communications Toxys
Toxys, Leiden University, and Leiden University Medical Center have agreed to commercialise and develop further the ToxProfiler technology invented at …
RedHill expands manufacturing capacity for opaganib with Cosmo
January 29, 2021Medical Communications RedHill Biopharma
RedHill Biopharma has announced a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib (Yeliva), to address …
EMA accepts Global Blood Therapeutics’ MAA for Oxbryta
January 28, 2021Global Blood Therapeutics
The EMA has accepted Global Blood Therapeutics (GBT)’s Marketing Authorisation Application (MAA) for Oxbryta (voxelotor) tablets, and has started its …
Pfizer-BioNTech COVID-19 vaccine effective against South Africa variant, companies say
January 28, 2021Pfizer and BioNTech have said that their COVID-19 vaccine is effective in protecting against the variant of the virus found …
Harbour BioMed’s Batoclimab granted Breakthrough Therapy designation in China
January 28, 2021Harbour BioMed
Harbour BioMed (HBM) has announced that China’s Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab, a …
Pfizer’s rheumatoid arthritis drug fails to meet safety criteria
January 28, 2021Pfizer
Pfizer has announced that its rheumatoid arthritis (RA) drug XELJANZ (tofacitinib) has failed to meet the co-primary endpoint in its …
Valneva begins production of its COVID-19 vaccine
January 28, 2021COVID-19, Valneva
Valneva, a specialty vaccine company focused on the prevention of infectious diseases with significant unmet medical needs, has commenced production …
NICE recommends Celgene’s REVLIMID for multiple myeloma
January 27, 2021Research and Development Cancer, Celgene
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment after an autologous stem cell …
Diurnal and Citrine sign licensing agreement for Alkindi
January 27, 2021Research and Development Citrine, Diurnal
Diurnal Group has entered into an exclusive licence agreement for its product Alkindi (hydrocortisone granules in capsules for opening) with …
MSD’s cancer therapy KEYTRUDA gets EU approval
January 26, 2021Manufacturing and Production Cancer, MSD
MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …
FDA approves Aurinia’s oral lupus nephritis therapy
January 26, 2021Manufacturing and Production Aurinia
The FDA has approved Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients …
AstraZeneca rejects “incorrect” claims about COVID-19 vaccine efficacy
January 26, 2021Manufacturing and Production AstraZeneca, COVID-19
AstraZeneca has rejected claims by German media that its COVID-19 vaccine has only 8% efficacy in over-65s. Two German newspapers, …
MSD discontinues development of COVID-19 vaccines
January 26, 2021Manufacturing and Production MSD, Merck
Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …
AbbVie’s psoriatic arthritis and ankylosing spondylitis drug gets EU approval
January 26, 2021Manufacturing and Production AbbVie
The European Commission (EC) has approved AbbVie’s RINVOQTM (upadacitinib 15 mg), an oral, once-daily selective and reversible JAK inhibitor for …
How COVID-19 has affected the oncology drugs market
January 25, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Cancer
In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas …
NovAliX and Chemical.AI announce drug discovery collaboration
January 25, 2021Sales and Marketing Chemical.AI, Novalix
NovAliX, a drug discovery-focused contract research organisation, and Chemical.AI, an artificial intelligence (AI) company, have announced a strategic collaboration in …
FDA approves Exelixis’ cancer drug Cabometyx
January 25, 2021Sales and Marketing Cancer, Exelixis
The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in …
New study challenges link between stress and migraines
January 25, 2021Sales and Marketing Curelator, migraine
Digital health platform Curelator has announced new data that shows a lack of association between increased stress and migraine attacks. …
Genentech announces positive top-line results for “wet” age-related macular degeneration antibody
January 25, 2021Sales and Marketing Genentech
Genentech has announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational …
